8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Mar 17, 2026·SEC
Clene Inc.(CLNN)Earnings, Financials & Key Ratios
CLNN•NASDAQ
$7.16
$72M mkt cap·Price updated May 6, 2026
AboutClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Show more
- Revenue$200K-41.5%
- EBITDA-$22M+31.4%
- Net Income-$26M+33.6%
- EPS (Diluted)-2.65+53.3%
- Gross Margin78.5%-1.3%
- EBITDA Margin-10794%-17.4%
- Operating Margin-11541.5%-19.3%
- Net Margin-13086.5%-13.6%
- Interest Coverage-8.61+1.0%
CLNN Key Insights
Clene Inc. (CLNN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Shares diluted 41.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CLNN Price & Volume
Clene Inc. (CLNN) stock price & volume — 10-year historical chart
Loading chart...
CLNN Growth Metrics
Clene Inc. (CLNN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-0.59%
3 Years-24.94%
TTM-41.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM33.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM55.62%
Return on Capital
10 Years-99.52%
5 Years-135.7%
3 Years-160.02%
Last Year-189.2%
CLNN Peer Comparison
Clene Inc. (CLNN) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 ACIU | 302.27M | 2.97 | -3.31 | -86.92% | -19.69% | -101.6% | 0.10 | |
 NRXP | 84.43M | 3.05 | -2.28 | -157.28% | ||||
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 |
Compare CLNN vs Peers
Clene Inc. (CLNN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLNN Income Statement
Clene Inc. (CLNN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 206K | 723K | 473K | 654K | 342K | 200K |
| Revenue Growth % | - | - | - | 250.97% | -34.58% | 38.27% | -47.71% | -41.52% |
| Cost of Goods Sold | 0 | 900K | 65K | 289K | 26K | 121K | 70K | 43K |
| COGS % of Revenue | - | - | 31.55% | 39.97% | 5.5% | 18.5% | 20.47% | 21.5% |
| Gross Profit | 0▲ 0% | -900K▲ 0% | 141K▲ 115.7% | 434K▲ 207.8% | 447K▲ 3.0% | 533K▲ 19.2% | 272K▼ 49.0% | 157K▼ 42.3% |
| Gross Margin % | - | - | 68.45% | 60.03% | 94.5% | 81.5% | 79.53% | 78.5% |
| Gross Profit Growth % | - | - | 115.67% | 207.8% | 3% | 19.24% | -48.97% | -42.28% |
| Operating Expenses | 323.94K | 15.43M | 20.36M | 50.41M | 48.86M | 41.07M | 33.37M | 23.24M |
| OpEx % of Revenue | - | - | 9881.07% | 6972.61% | 10328.96% | 6280.28% | 9755.85% | 11620% |
| Selling, General & Admin | 323.94K | 6.67M | 3.26M | 18.81M | 16.16M | 14.42M | 13.31M | 9.23M |
| SG&A % of Revenue | - | - | 1583.5% | 2602.07% | 3417.12% | 2204.59% | 3890.94% | 4614.5% |
| Research & Development | 6.64M | 8.76M | 15.2M | 28.42M | 31.92M | 26.66M | 20.06M | 14.01M |
| R&D % of Revenue | - | - | 7380.58% | 3930.29% | 6748.41% | 4075.69% | 5864.91% | 7005.5% |
| Other Operating Expenses | 0 | 0 | 1.89M | 3.18M | 773K | 0 | 0 | 0 |
| Operating Income | -323.94K▲ 0% | -16.33M▼ 4941.7% | -20.21M▼ 23.8% | -49.98M▼ 147.2% | -48.41M▲ 3.1% | -40.54M▲ 16.3% | -33.09M▲ 18.4% | -23.08M▲ 30.2% |
| Operating Margin % | - | - | -9812.62% | -6912.59% | -10234.46% | -6198.78% | -9676.32% | -11541.5% |
| Operating Income Growth % | - | -4941.67% | -23.77% | -147.24% | 3.14% | 16.26% | 18.37% | 30.25% |
| EBITDA | 348.06K | -15.43M | -19.25M | -49.02M | -47.39M | -38.84M | -31.45M | -21.59M |
| EBITDA Margin % | - | - | -9345.15% | -6780.5% | -10019.03% | -5938.07% | -9195.32% | -10794% |
| EBITDA Growth % | - | -4533.72% | -24.75% | -154.65% | 3.33% | 18.05% | 19.02% | 31.35% |
| D&A (Non-Cash Add-back) | 672K | 900K | 963K | 955K | 1.02M | 1.71M | 1.65M | 1.5M |
| EBIT | 19.43K | -16.07M | -17.92M | -9.3M | -26.62M | -44.95M | -35.34M | -23.08M |
| Net Interest Income | 343.37K | -88K | -950K | -870K | -3.3M | -3.17M | -3.2M | -2.46M |
| Interest Income | 343.37K | 0 | 0 | 0 | 0 | 1.39M | 865K | 223K |
| Interest Expense | 0 | 88K | 950K | 870K | 3.3M | 4.56M | 4.06M | 2.68M |
| Other Income/Expense | 343.37K | 177K | 1.34M | 39.81M | 18.49M | -8.96M | -6.31M | -3.09M |
| Pretax Income | 19.43K▲ 0% | -16.16M▼ 83248.9% | -18.87M▼ 16.8% | -10.17M▲ 46.1% | -29.92M▼ 194.2% | -49.5M▼ 65.5% | -39.4M▲ 20.4% | -26.17M▲ 33.6% |
| Pretax Margin % | - | - | -9160.68% | -1406.36% | -6325.16% | -7569.42% | -11520.47% | -13086.5% |
| Income Tax | 0 | 0 | 406K | -428K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | -2.15% | 4.21% | 0% | 0% | 0% | 0% |
| Net Income | -277.31K▲ 0% | -16.16M▼ 5725.6% | -19.28M▼ 19.3% | -9.74M▲ 49.5% | -29.92M▼ 207.2% | -49.5M▼ 65.5% | -39.4M▲ 20.4% | -26.17M▲ 33.6% |
| Net Margin % | - | - | -9357.77% | -1347.16% | -6325.16% | -7569.42% | -11520.47% | -13086.5% |
| Net Income Growth % | - | -5725.59% | -19.33% | 49.47% | -207.17% | -65.47% | 20.41% | 33.57% |
| Net Income (Continuing) | 19.43K | -16.16M | -19.28M | -9.74M | -29.92M | -49.5M | -39.4M | -26.17M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.09▲ 0% | -4.69▼ 5175.6% | -5.51▼ 17.5% | -3.16▲ 42.6% | -4.69▼ 48.4% | -9.43▼ 101.1% | -5.67▲ 39.9% | -2.65▲ 53.3% |
| EPS Growth % | - | -5175.59% | -17.48% | 42.65% | -48.42% | -101.07% | 39.87% | 53.26% |
| EPS (Basic) | -0.09 | -4.69 | -5.51 | -3.16 | -4.69 | -9.43 | -5.67 | -2.65 |
| Diluted Shares Outstanding | 3.12M | 3.47M | 3.5M | 3.08M | 3.26M | 5.25M | 6.95M | 9.86M |
| Basic Shares Outstanding | 3.12M | 3.47M | 3.5M | 3.08M | 3.26M | 5.25M | 6.95M | 9.86M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CLNN Balance Sheet
Clene Inc. (CLNN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 790.48K | 9.48M | 62.99M | 54.58M | 29.2M | 38.85M | 16.16M | 8.98M |
| Cash & Short-Term Investments | 743.78K | 8.79M | 59.27M | 50.29M | 23.32M | 35M | 12.15M | 5.19M |
| Cash Only | 743.78K | 8.79M | 59.27M | 50.29M | 18.33M | 28.82M | 12.15M | 5.19M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 4.98M | 6.18M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 2.17M | 1.61M | 2.97M | 1.34M | 391K | 0 |
| Days Sales Outstanding | - | - | 3.84K | 814.31 | 2.29K | 746.74 | 417.3 | - |
| Inventory | 0 | 28K | 191K | 41K | 43K | 37K | 68K | 37K |
| Days Inventory Outstanding | - | 11.36 | 1.07K | 51.78 | 603.65 | 111.61 | 354.57 | 314.07 |
| Other Current Assets | 0 | 248K | 112K | 2.45M | 2.87M | 2.48M | 137K | 3.75M |
| Total Non-Current Assets | 46.37M | 5.4M | 5.25M | 8.48M | 15.3M | 13.49M | 11.18M | 9.15M |
| Property, Plant & Equipment | 4.47M | 5.4M | 5.25M | 8.42M | 15.24M | 13.43M | 11.12M | 9.1M |
| Fixed Asset Turnover | - | - | 0.04x | 0.09x | 0.03x | 0.05x | 0.03x | 0.02x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 46.37M | 0 | 0 | 58K | 58K | 0 | 58K | 58K |
| Other Non-Current Assets | -4.47M | 0 | 0 | 0 | 0 | 58K | 0 | 0 |
| Total Assets | 47.16M▲ 0% | 14.88M▼ 68.5% | 68.24M▲ 358.7% | 63.06M▼ 7.6% | 44.49M▼ 29.4% | 52.34M▲ 17.6% | 27.34M▼ 47.8% | 18.13M▼ 33.7% |
| Asset Turnover | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
| Asset Growth % | - | -68.45% | 358.71% | -7.59% | -29.45% | 17.64% | -47.77% | -33.68% |
| Total Current Liabilities | 222.24K | 4.31M | 11.67M | 6.03M | 13.86M | 25.33M | 10.29M | 10.78M |
| Accounts Payable | 0 | 889K | 1.12M | 1.92M | 3.01M | 1.5M | 1.24M | 892K |
| Days Payables Outstanding | - | 360.54 | 6.31K | 2.43K | 42.31K | 4.54K | 6.47K | 7.57K |
| Short-Term Debt | 3M | 416K | 0 | 0 | 6.42M | 19.5M | 359K | 4.88M |
| Deferred Revenue (Current) | -4.1M | 80K | 413K | 0 | 0 | 0 | 2.67M | 0 |
| Other Current Liabilities | 68K | 2.11M | 7.15M | 520K | 0 | 2.12M | 0 | 5M |
| Current Ratio | 3.56x | 2.20x | 5.40x | 9.06x | 2.11x | 1.53x | 1.57x | 0.83x |
| Quick Ratio | 3.56x | 2.19x | 5.38x | 9.05x | 2.10x | 1.53x | 1.56x | 0.83x |
| Cash Conversion Cycle | - | - | -1.4K | -1.56K | -39.42K | -3.68K | -5.69K | - |
| Total Non-Current Liabilities | 41.94M | 5.68M | 56.23M | 44.44M | 27.4M | 13.62M | 25.9M | 24.95M |
| Long-Term Debt | 0 | 640K | 1.95M | 19.08M | 19.25M | 7.15M | 15.43M | 13.54M |
| Capital Lease Obligations | 224K | 1.82M | 1.99M | 4.47M | 5.59M | 4.9M | 4.13M | 3.25M |
| Deferred Tax Liabilities | -224K | 0 | 260K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 39.87M | 1.37M | 52.03M | 20.89M | 2.56M | 1.57M | 6.34M | 8.16M |
| Total Liabilities | 42.16M | 9.99M | 67.9M | 50.47M | 41.26M | 38.95M | 36.19M | 35.72M |
| Total Debt | 3.22M | 2.88M | 4.32M | 24.04M | 31.82M | 32.16M | 20.84M | 21.67M |
| Net Debt | 2.48M | -5.91M | -54.95M | -26.25M | 13.49M | 3.34M | 8.69M | 16.48M |
| Debt / Equity | 0.64x | 0.59x | 12.68x | 1.91x | 9.83x | 2.40x | - | - |
| Debt / EBITDA | 9.26x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 7.13x | - | - | - | - | - | - | - |
| Interest Coverage | - | -182.58x | -18.86x | -10.69x | -8.08x | -9.86x | -8.69x | -8.61x |
| Total Equity | 5M▲ 0% | 4.89M▼ 2.3% | 341K▼ 93.0% | 12.6M▲ 3594.1% | 3.24M▼ 74.3% | 13.39M▲ 313.7% | -8.86M▼ 166.1% | -17.59M▼ 98.6% |
| Equity Growth % | - | -2.26% | -93.02% | 3594.13% | -74.3% | 313.65% | -166.15% | -98.62% |
| Book Value per Share | 1.60 | 1.41 | 0.10 | 4.09 | 0.99 | 2.55 | -1.27 | -1.78 |
| Total Shareholders' Equity | 5M | 4.89M | 341K | 12.6M | 3.24M | 13.39M | -8.86M | -17.59M |
| Common Stock | 199 | 2K | 6K | 6K | 7K | 13K | 1K | 1K |
| Retained Earnings | 17.04K | -69.57M | -153.56M | -163.3M | -193.22M | -242.72M | -282.12M | -308.3M |
| Treasury Stock | -1.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 27.18K | 41K | 325K | 233K | 203K | 199K | 71K | 172K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLNN Cash Flow Statement
Clene Inc. (CLNN) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -205.37K | -13.2M | -18.93M | -34.62M | -39.01M | -30.17M | -21.33M | -18.55M |
| Operating CF Margin % | - | - | -9188.84% | -4788.94% | -8247.57% | -4613.3% | -6235.67% | -9273% |
| Operating CF Growth % | - | -6325.9% | -43.43% | -82.92% | -12.67% | 22.66% | 29.32% | 13.04% |
| Net Income | -277.31K | -16.16M | -19.28M | -9.74M | -29.92M | -49.5M | -39.4M | -26.17M |
| Depreciation & Amortization | 672K | 848K | 963K | 955K | 1.02M | 1.71M | 1.65M | 1.5M |
| Stock-Based Compensation | 269K | 399K | 761K | 12.38M | 8.51M | 9.12M | 7.95M | 6.38M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -46.6K | 554K | 1.97M | -39.23M | -17.09M | 8.7M | 5.26M | 3.1M |
| Working Capital Changes | 118.54K | 1.16M | -3.35M | 1M | -1.54M | -191K | 3.21M | -3.35M |
| Change in Receivables | 0 | 0 | -21K | -28K | -140K | 46K | 79K | 64K |
| Change in Inventory | 0 | -28K | -163K | 150K | -2K | 6K | -31K | 31K |
| Change in Payables | 0 | -76K | -312K | 1.27M | 285K | -1.51M | -264K | -348K |
| Cash from Investing | -46M | -294K | -387K | -1.33M | -10.16M | -1.5M | 6.32M | -39K |
| Capital Expenditures | -752K | -294K | -387K | -1.33M | -5.18M | -330K | -15K | -39K |
| CapEx % of Revenue | - | - | 187.86% | 184.23% | 1094.93% | 50.46% | 4.39% | 19.5% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 46.95M | 5.5M | 69.53M | 27.11M | 17.25M | 42.16M | -1.53M | 11.52M |
| Debt Issued (Net) | 3.88M | -3.18M | 5.93M | 19.84M | 5.56M | 269K | -10.9M | -384K |
| Equity Issued (Net) | 0 | 8.07M | 35.05M | 9.25M | 11.46M | 42.09M | 9.24M | 10.4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 15.9M | 610K | 28.55M | -1.98M | 229K | -200K | 124K | 1.5M |
| Net Change in Cash | 787.78K▲ 0% | -7.99M▼ 1114.1% | 50.49M▲ 732.0% | -8.93M▼ 117.7% | -31.96M▼ 257.9% | 10.49M▲ 132.8% | -16.67M▼ 258.9% | -6.97M▲ 58.2% |
| Free Cash Flow | -957.37K▲ 0% | -13.49M▼ 1309.2% | -19.32M▼ 43.2% | -35.96M▼ 86.1% | -44.19M▼ 22.9% | -30.5M▲ 31.0% | -21.34M▲ 30.0% | -18.59M▲ 12.9% |
| FCF Margin % | - | - | -9376.7% | -4973.17% | -9342.49% | -4663.76% | -6240.06% | -9292.5% |
| FCF Growth % | - | -1309.17% | -43.18% | -86.15% | -22.9% | 30.98% | 30.03% | 12.91% |
| FCF per Share | -0.31 | -3.89 | -5.52 | -11.68 | -13.55 | -5.81 | -3.07 | -1.89 |
| FCF Conversion (FCF/Net Income) | 0.74x | 0.82x | 0.98x | 3.55x | 1.30x | 0.61x | 0.54x | 0.71x |
| Interest Paid | 0 | 48K | 39K | 1.09M | 2.32M | 3.06M | 2.61M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLNN Key Ratios
Clene Inc. (CLNN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -5.55% | -326.79% | -737.45% | -150.56% | -377.9% | -595.47% | -1738.36% | - |
| Return on Invested Capital (ROIC) | - | -379.33% | - | - | -2357.58% | -181.74% | -299.74% | - |
| Gross Margin | - | - | 68.45% | 60.03% | 94.5% | 81.5% | 79.53% | 78.5% |
| Net Margin | - | - | -9357.77% | -1347.16% | -6325.16% | -7569.42% | -11520.47% | -13086.5% |
| Debt / Equity | 0.64x | 0.59x | 12.68x | 1.91x | 9.83x | 2.40x | - | - |
| Interest Coverage | - | -182.58x | -18.86x | -10.69x | -8.08x | -9.86x | -8.69x | -8.61x |
| FCF Conversion | 0.74x | 0.82x | 0.98x | 3.55x | 1.30x | 0.61x | 0.54x | 0.71x |
| Revenue Growth | - | - | - | 250.97% | -34.58% | 38.27% | -47.71% | -41.52% |
CLNN SEC Filings & Documents
Clene Inc. (CLNN) SEC filings — annual & quarterly reports (10-K, 10-Q)
CLNN Frequently Asked Questions
Clene Inc. (CLNN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Clene Inc. (CLNN) reported $0.2M in revenue for fiscal year 2025.
Clene Inc. (CLNN) saw revenue decline by 41.5% over the past year.
Clene Inc. (CLNN) reported a net loss of $26.2M for fiscal year 2025.
Dividend & Returns
Clene Inc. (CLNN) had negative free cash flow of $18.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More CLNN
Clene Inc. (CLNN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates